Fixed dose drug combinations–are they pharmacoeconomically sound? Findings and implications especially for lower-and middle-income countries

B Godman, H McCabe, TD Leong… - Expert review of …, 2020 - Taylor & Francis
Introduction There are positive aspects regarding the prescribing of fixed dose combinations
(FDCs) versus prescribing the medicines separately. However, these have to be balanced …

The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?

M Vitoria, A Hill, N Ford, M Doherty, P Clayden… - Aids, 2018 - journals.lww.com
There are currently approximately 16 million people taking NNRTI-based first-line treatment
in low-income and middle-income countries. Most of these patients are using the …

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA Panel

MS Saag, CA Benson, RT Gandhi, JF Hoy… - Jama, 2018 - jamanetwork.com
Importance Antiretroviral therapy (ART) is the cornerstone of prevention and management of
HIV infection. Objective To evaluate new data and treatments and incorporate this …

Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research

J Dorward, R Lessells, PK Drain, K Naidoo… - The lancet HIV, 2018 - thelancet.com
A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled
out in low-income and middle-income countries (LMICs). In studies from predominantly high …

Management of virologic failure and HIV drug resistance

SM McCluskey, MJ Siedner… - Infectious Disease Clinics, 2019 - id.theclinics.com
In 2014, the Joint United Nations Programme on HIV and AIDS established global targets
such that 90% of people with HIV will be diagnosed, 90% of those diagnosed will be on …

Advanced HIV: diagnosis, treatment, and prevention

S Prabhu, JI Harwell, N Kumarasamy - The lancet HIV, 2019 - thelancet.com
Substantial progress has been made this century in bringing millions of people living with
HIV into care, but progress for early HIV diagnosis has stalled. Individuals first diagnosed …

HIV drug resistance in low-income and middle-income countries

RL Hamers, TFR de Wit, CB Holmes - The Lancet HIV, 2018 - thelancet.com
After 15 years of global scale-up of antiretroviral therapy (ART), rising prevalence of HIV
drug resistance in many low-income and middle-income countries (LMICs) poses a growing …

Management of active tuberculosis in adults with HIV

G Meintjes, JCM Brust, J Nuttall, G Maartens - The Lancet HIV, 2019 - thelancet.com
Every year, about 1 million people living with HIV worldwide develop tuberculosis. Although
the drug regimens used to treat tuberculosis in these patients are the same as those used in …

Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: rare but possible

MJ Pena, N Chueca, A D'avolio… - Open Forum …, 2019 - academic.oup.com
We describe a case of virological failure during initial treatment with tenofovir disoproxil
fumarate/emtricitabine/dolutegravir twice daily, with concomitant rifampin treatment of …

Tuberculosis and HIV—An Update on the “cursed duet” in children

SHL Fry, SL Barnabas, MF Cotton - Frontiers in pediatrics, 2019 - frontiersin.org
HIV and tuberculosis (TB) often occur together with each exacerbating the other.
Improvements in vertical transmission prevention has reduced the number of HIV-infected …